An integrated transmission surface plasmon resonance platform with microfluidic sensor has a high potential to be a medical diagnostic tool. There has been extensive research into the potential use of transmission surface plasmon resonance, but here we demonstrate the practical application of transmission surface plasmon resonance to monitor and compare the urinary microRNA expression between the urothelial cell carcinoma patient group and the healthy control group. Furthermore, the expression levels are compared with the conventional real-time quantitative polymerase chain reaction method to verify the results. The relative expression of miR-21–3p and miR–214–3p have demonstrated to be upregulated in urothelial cell carcinoma patient group when measured using both real-time quantitative polymerase chain reaction and transmission surface plasmon resonance. Using receiver operating characteristics of miR-21–3p and miR-214–3p the area under curve reaches an excellent score of 0.99 and 0.917, respectively. Our work has demonstrated the ability of clinical application of transmission surface plasmon resonance as a rapid and cost effective point-of-care.
ASJC Scopus subject areas